A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study (Q33497562)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study |
scientific article |
Statements
1 reference
A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study (English)
1 reference
Rose PG
1 reference
Blessing JA
1 reference
Lewandowski GS
1 reference
Creasman WT
1 reference
Webster KD
1 reference
1 reference
Identifiers
1 reference